EUVIMEDEUVIMED entdecken
Open Access

Pathologic Processing of Lung Cancer Resection Specimens After Neoadjuvant Therapy

Annikka Weissferdt, Cheuk H Leung, Heather Lin, Boris Sepesi, William N William, Stephen G Swisher, Tina Cascone, J Jack Lee, Abujiang Pataer

Modern Pathology · 2024-01 · 37 (1) · 100353

DOI: 10.1016/j.modpat.2023.100353 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Pathology, 2024-01. Verfasst von Annikka Weissferdt und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Cardiovascular and …. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Khalifa Bin Zayed Al Nahyan Foundation, Bristol-Myers Squibb Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neoadjuvant treatment of non-small cell lung cancer challenges the traditional processing of pathology specimens. Induction therapy before resection allows evaluation of the efficacy of neoadjuvant agents at the time of surgery. Many clinical trials use pathologic tumor response, measured as major pathologic response (MPR, ≤10% residual viable tumor [RVT]) or complete pathologic response (CPR, 0% RVT) as a surrogate of clinical efficacy. Consequently, accurate pathologic evaluation of RVT is crucial. However, pathologic assessment has not been uniform, which is particularly true for sampling of the primary tumor, which instead of the traditional processing, requires different tissue submission because the focus has shifted from tumor typing alone to RVT scoring. Using a simulation study, we analyzed the accuracy rates of %RVT, MPR, and CPR of 31 pretreated primary lung tumors using traditional grossing compared with the gold standard of submitting the entire residual primary tumor and identified the minimum number of tumor sections to be submitted to ensure the most accurate scoring of %RVT, MPR, and CPR. Accurate %RVT, MPR, and CPR calls were achieved in 52%, 87%, and 81% of cases, respectively, using the traditional grossing method. Accuracy rates of at least 90% for these parameters require either submission of all residual primary tumor or at least 20 tumor sections. Accurate %RVT, MPR, and CPR scores cannot be achieved with traditional tumor grossing. Submission of the entire primary tumor, up to a maximum of 20 sections, is required for the most accurate reads.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsCarcinoma, Non-Small-Cell LungHumansNeoadjuvant TherapyLungTreatment Outcome

Stichwörter der Autor:innen

CPRMPRNSCLCneoadjuvant treatmentpathologic responsetumor processing

Autor:innen und Institutionen

  • Department of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Cardiovascular and Thoracic Surgery, The University of Texas MD Anderson Cancer Center, H…
  • Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Department of Cardiovascular and Thoracic Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Hospital BP, a Beneficencia Portuguesa de Sao Paulo, Sao Paulo, Brazil; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Förderung

  • NCI NIH HHS
  • Khalifa Bin Zayed Al Nahyan Foundation
  • Bristol-Myers Squibb Company
  • National Cancer Institute
  • NIH
  • University of Texas MD Anderson Cancer Center

Zitieren

APA

Weissferdt, A., Leung, C. H., Lin, H., Sepesi, B., William, W. N., Swisher, S. G., Cascone, T., Lee, J. J., & Pataer, A. (2024). Pathologic Processing of Lung Cancer Resection Specimens After Neoadjuvant Therapy. Modern Pathology, 37(1), 100353. https://doi.org/10.1016/j.modpat.2023.100353

Vancouver

Weissferdt A, Leung CH, Lin H, Sepesi B, William WN, Swisher SG, et al. Pathologic Processing of Lung Cancer Resection Specimens After Neoadjuvant Therapy. Modern Pathology. 2024;37(1):100353. doi:10.1016/j.modpat.2023.100353

BibTeX
@article{Weissferdt2024,
  author = {Weissferdt, Annikka and Leung, Cheuk H and Lin, Heather and Sepesi, Boris and William, William N and Swisher, Stephen G and Cascone, Tina and Lee, J Jack and Pataer, Abujiang},
  title = {Pathologic Processing of Lung Cancer Resection Specimens After Neoadjuvant Therapy},
  journal = {Modern Pathology},
  year = {2024},
  volume = {37},
  number = {1},
  pages = {100353},
  doi = {10.1016/j.modpat.2023.100353}
}
Kostenlos starten →